( 100% );
10%
10%
( 100% ).
,
( 100% ):
10%
10%
( 100% ):
, :
10% -10,0 /
10% 10,0 /
: .
:
;
;
( );
(, , ).
.
1 3 ; 1 .
1 6 ( );
- ;
, 1 7-10 . 1 3-6 :
1,0-1,28 /;
0,81-1,45 / ( , ),
>2,5 , <10 .
, [11,12,13]
(, , , );
, .
(: 2): 2014
***
:
( , , ).
:
().
I. , 2014
1. 1) Bilezikian JP, Khan A, Potts JT., Jr Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the Third International Workshop. J Clin Endocrinol Metab. 2009;94:335339. 2)Marx SJ. Hyperparathyroid and hypoparathyroid disorders. New Engl J Med. 2000;343:18631875. [PubMed] 3) Hypoparathyroidism Association Inc website. HPTH Association Inc; Idaho Falls, ID, USA: 2011. [PubMed] 4) .., .. . . 2006 5) .. , 9(352) 2006. 6)Winer KK, Yanovski JA, Cutler GB., Jr Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA. 1996;276:631636. [PubMed] 7)Winer KK, Yanovski JA, Sarani B, Cutler GB., Jr A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab. 1998;83:34803486. [PubMed] 8)Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: A randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003;88:42144220. [PubMed] 9)Winer KK, Sinaii N, Peterson D, Sainz B, Jr, Cutler GB., Jr Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab. 2008;93:33893395. [PMC free article] [PubMed] 10) Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB. Long-term treatment of 12 children with chronic hypoparathyroidism: A randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab. 2010;95:26802688. [PMC free article] [PubMed] 11) Shoback D. Hypoparathyroidism. N Engl J Med. 2008;359:391403. [PubMed] 12) Maeda SS, Fortes EM, Oliveira UM, Borba VC, Lazaretti-Castro M. Hypoparathyroidism and pseudohypoparathyroidism. Arq Bras Endocrinol Metab. 2006;50:664673. [PubMed] 13) Noordzij M, Voormolen NMC, Boeschoten EW, et al. Disordered mineral metabolism is not a risk factor for loss of residual renal function in dialysis patients. Nephrol Dial Transplant. 2009;24:15801587. [PubMed]
|
|
|
(: 2): 2014
III.
:
1) ., ..., , ..
2) .., ..., ..
3) .., ..., .
: .
:
, .. , .
: 3 / / .
